None of any substance known, short term, other than chief executive officer, Brian Lian, will deliver a corporate presentation at the 11th Annual Biotech Showcase™ later in the month.........long term, the company is prepping for more biopsy testing of its drugs, both VK2809 in NASH and VK5211, “an orally available, non-steroidal SARM designed to selectively stimulate muscle and bone formation.”.
Question...is there a short term catalyst or forward event coming thanks 'bUrRpPPP!'
However, as this is a close knit sector with limited current players possessing potential for FDA approval. A buy-out offer is always an immediate possibility, that along with any positive new from others seems to move the top potentials in the sector as a whole, although temporarily when it happens.
News 
Market Data 
Discover 
